SSA
ENGN icon

Schonfeld Strategic Advisors’s enGene Therapeutics ENGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,645
Closed -$150K – 2340
2025
Q4 		$150K Sell
16,645
-8,425
-34% -$67.5K ﹤0.01% 1767
2025
Q3 		$171K Sell
25,070
-149,500
-86% -$682K ﹤0.01% 1970
2025
Q2 		$635K Buy
174,570
+40,486
+30% +$152K ﹤0.01% 1469
2025
Q1 		$601K Buy
134,084
+1,824
+1% +$11.3K ﹤0.01% 1507
2024
Q4 		$880K Sell
132,260
-173,774
-57% -$1.35M 0.01% 1171
2024
Q3 		$2.02M Buy
306,034
+209,034
+215% +$1.55M 0.01% 877
2024
Q2 		$915K Buy
97,000
+46,300
+91% +$594K 0.01% 1239
2024
Q1 		$859K Buy
+50,700
New +$620K 0.01% 1293

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Schonfeld Strategic Advisors's ENGN Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 16,645 shares — an estimated $150K sold.

Schonfeld Strategic Advisors first reported a position in ENGN in Q1 2024 and held it in 8 quarters. The position peaked at $2.02M in Q3 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 16,645 enGene Therapeutics shares in Q1 2026, an estimated $150K.
  • Schonfeld Strategic Advisors first reported a position in enGene Therapeutics in Q1 2024 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's enGene Therapeutics position peaked at $2.02M in Q3 2024.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.